Mucosal-associated invariant T cell is a potential marker to distinguish fibromyalgia syndrome from arthritis

Chie Sugimoto1, Takahiko Konno2, Rika Wakao3

  • 1Department of Hygiene & Cellular Preventive Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, 060-8638, Japan.

Plos One
|April 9, 2015
PubMed
Abstract

Insights

Researchers identified mucosal-associated invariant T (MAIT) cells as potential biomarkers for diagnosing fibromyalgia (FMS), rheumatoid arthritis (RA), and spondyloarthritis (SpA). MAIT cell analysis offers a more objective diagnostic standard for these conditions with similar symptoms.

Area of Science:

  • Immunology
  • Rheumatology
  • Pain Medicine

Background:

  • Fibromyalgia (FMS) is characterized by widespread pain, often viewed as a disorder or psychosomatic condition due to a lack of objective evidence.
  • FMS shares symptoms with rheumatoid arthritis (RA) and spondyloarthritis (SpA), complicating differential diagnosis.
  • The study aimed to find objective biomarkers in blood to aid FMS diagnosis and differentiate it from RA and SpA.

Purpose of the Study:

  • To identify disease-specific biomarkers for fibromyalgia (FMS).
  • To differentiate FMS from rheumatoid arthritis (RA) and spondyloarthritis (SpA) using objective measures.
  • To explore the role of mucosal-associated invariant T (MAIT) cells in these conditions.

Main Methods:

  • Peripheral blood mononuclear cells (PBMCs) were collected from FMS patients, RA patients, SpA patients, and healthy donors (HD).
  • Multicolor flow cytometry was used to analyze the percentage of MAIT cells and cell surface antigen expression.
  • Specific chemokine receptors, NK receptors, and other cell surface markers on MAIT cells were quantified.

Main Results:

  • MAIT cell populations were decreased in FMS, RA, and SpA patients compared to HD.
  • Specific MAIT cell surface markers (e.g., CCR4, CCR7, CXCR1, NKp80, CD150, CD107a, CD8β) showed potential as biomarkers for FMS.
  • Distinct markers were identified for RA (CD44, CXCR1) and SpA (CXCR4) to differentiate them from FMS; drug treatment affected MAIT cell marker expression in FMS.

Conclusions:

  • MAIT cell analysis, alongside existing diagnostic methods, provides a more objective standard for diagnosing FMS, RA, and SpA.
  • This approach can help distinguish between these conditions with overlapping clinical presentations.
  • Objective biomarkers derived from MAIT cell analysis may reduce diagnostic ambiguity and patient prejudice.